BiotechTube

Aspirin, Clopidogrel

Pre-clinicalCompleted
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ischemic Stroke

Conditions

Ischemic Stroke

Trial Timeline

Apr 1, 2019 → Jan 3, 2022

NCT ID
NCT03823274

About Aspirin, Clopidogrel

Aspirin, Clopidogrel is a pre-clinical stage product being developed by Yuhan for Ischemic Stroke. The current trial status is completed. This product is registered under clinical trial identifier NCT03823274. Target conditions include Ischemic Stroke.

What happened to similar drugs?

10 of 14 similar drugs in Ischemic Stroke were approved

Approved (10) Terminated (3) Active (4)
✅RegadenosonAstellas PharmaApproved
✅StatinShionogiApproved
✅RepathaAmgenApproved
✅Oral Anticoagulant + Antiplatelet DrugPfizerApproved
✅celecoxib + ibuprofen + placeboPfizerApproved
✅Eplerenone + Placebo or sugar pillPfizerApproved
✅Enoxaparin sodiumSanofiApproved

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03823274Pre-clinicalCompleted

Competing Products

20 competing products in Ischemic Stroke

See all competitors
ProductCompanyStageHype Score
DS-1040b + PlaceboDaiichi SankyoPhase 1/2
32
DS-1040b + AspirinDaiichi SankyoPhase 1
29
DS1040b + PlaceboDaiichi SankyoPre-clinical
26
Pharmacological intensification based on olmesartanDaiichi SankyoPhase 2
35
RegadenosonAstellas PharmaPhase 1
29
YM872 (zonampanel), t-PA (alteplase)Astellas PharmaPhase 2
35
RegadenosonAstellas PharmaApproved
43
ASP2246Astellas PharmaPhase 1/2
39
Gadolinium + AdenosineAstellas PharmaPhase 2/3
38
XY03-EA + XY03-EA PlaceboSun PharmaceuticalPhase 2
31
Redasemtide + PlaceboShionogiPhase 2
39
StatinShionogiApproved
43
fospropofol + propofolEisaiPhase 2
35
PDE5 InhibitorsEli LillyPre-clinical
26
SB623 Implant (2.5M) + SB623 Implant (5.0M)Sumitomo PharmaPhase 2
35
Mesenchymal stem cell + PlaceboRohto PharmaceuticalPhase 2
42
Elezanumab + PlaceboAbbViePhase 2
35
Balovaptan + PlaceboRochePhase 2
27
RepathaAmgenApproved
35
GS-6615 + PlaceboGilead SciencesPhase 1
29